摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-甲基-2-(1,3-噻唑-2-基)乙酰胺 | 216970-94-4

中文名称
N-甲基-2-(1,3-噻唑-2-基)乙酰胺
中文别名
——
英文名称
N-methyl 2-(2-thiazolyl)acetamide
英文别名
N-methyl thiazol-2-ylacetamide;N-methyl-2-(1,3-thiazol-2-yl)acetamide
N-甲基-2-(1,3-噻唑-2-基)乙酰胺化学式
CAS
216970-94-4
化学式
C6H8N2OS
mdl
——
分子量
156.208
InChiKey
TZSYLUPOTIZPIM-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    340.2±25.0 °C(Predicted)
  • 密度:
    1.226±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.2
  • 重原子数:
    10
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.33
  • 拓扑面积:
    70.2
  • 氢给体数:
    1
  • 氢受体数:
    3

反应信息

  • 作为反应物:
    描述:
    (E)-3-(dimethylamino)-1,2-dipyridin-4-ylprop-2-en-1-one 、 N-甲基-2-(1,3-噻唑-2-基)乙酰胺 生成 1-methyl-3-(pyridin-4-yl)-5-(thiazol-2-yl)-1H-[2,4']bipyridinyl-6-one
    参考文献:
    名称:
    Substituted 1H-pyridinyl-2-ones as GABAA alpha 2/3 ligands
    摘要:
    根据式(I)的化合物或其盐是选择性的GABAA受体配体,用于治疗中枢神经系统疾病。
    公开号:
    US06352994B2
  • 作为产物:
    描述:
    diethyl 2-[thiazol-2-(3H-ylidene)]malonate 在 sodium chloride 作用下, 以 乙醇二甲基亚砜 为溶剂, 反应 5.5h, 生成 N-甲基-2-(1,3-噻唑-2-基)乙酰胺
    参考文献:
    名称:
    3-Heteroaryl-2-pyridones:  Benzodiazepine Site Ligands with Functional Selectivity for α2/α3-Subtypes of Human GABAA Receptor-Ion Channels
    摘要:
    A novel series of 3-heteroaryl-5,6-bis(aryl)-1-methyl-2-pyridones were developed with high affinity for the benzodiazepine (BZ) binding site of human gamma-aminobutyric acid (GABA(A)) receptor ion channels, low binding selectivity for alpha2- and/or alpha3- over alpha1-containing GABA(A) receptor subtypes and high binding selectivity over alpha5 subtypes. High affinity appeared to be associated with a coplanar conformation of the pyridone and sulfur-containing 3-heteroaryl rings resulting from an attractive S...O intramolecular interaction. Functional selectivity (i.e., selective efficacy) for alpha2 and/or alpha3 GABA(A) receptor subtypes over alpha1 was observed in several of these compounds in electrophysiological assays. Furthermore, an alpha3 subtype selective inverse agonist was proconvulsant and anxiogenic in rodents while an alpha2/alpha3 subtype selective partial agonist was anticonvulsant and anxiolytic, supporting the hypothesis that subtype selective BZ site agonists may provide new anxiolytic therapies.
    DOI:
    10.1021/jm0110789
  • 作为试剂:
    描述:
    4-哒嗪羧酸N-methyl-2-(4-methylthiazol-2-yl)acetamideN-甲基-2-(1,3-噻唑-2-基)乙酰胺 为溶剂, 生成 5-(4-methoxyphenyl)-1-methyl-3-(4-methylthiazol-2-yl)-6-pyridazin-4-yl-1H-pyridin-2-one
    参考文献:
    名称:
    Substituted 1H-pyridinyl-2-ones as GABAA-&agr; 2/3 ligands
    摘要:
    取代的1H-吡啶基-2-酮可作为GABAA-Alpha 2/3配体。
    公开号:
    US06200982B1
点击查看最新优质反应信息

文献信息

  • SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS
    申请人:Yuan Haiqing
    公开号:US20120157487A1
    公开(公告)日:2012-06-21
    The present invention relates to novel sulfur derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors.
    本发明涉及新型生物、其制备方法、含有它们的制药组合物以及它们作为化学因子受体调节剂的药物使用。
  • N-SULFONYLATED TETRAHYDROQUINOLINES AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE
    申请人:Glick Gary D.
    公开号:US20140088094A1
    公开(公告)日:2014-03-27
    The invention provides tetrahydroquinoline and related compounds, pharmaceutical compositions, methods of inhibiting RORγ activity, reducing the amount of IL-17 in a subject, and treating immune disorders and inflammatory disorders using such tetrahydroquinoline and related compounds are provided.
    本发明提供四氢喹啉及相关化合物、制药组合物、抑制RORγ活性的方法、减少受试者体内IL-17的数量以及使用该四氢喹啉及相关化合物治疗免疫性疾病和炎症性疾病的方法。
  • SUBSTITUTED 1H-PYRIDINYL-2-ONES AS GABA A?ALPHA 2/3 LIGANDS
    申请人:MERCK SHARP & DOHME LTD.
    公开号:EP0994873A1
    公开(公告)日:2000-04-26
  • PHOSPHODIESTERASE 4 INHIBITORS
    申请人:Memory Pharmaceuticals Corporation
    公开号:EP1802615A1
    公开(公告)日:2007-07-04
  • US6200982B1
    申请人:——
    公开号:US6200982B1
    公开(公告)日:2001-03-13
查看更多